The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer
Yıl: 2016 Cilt: 25 Sayı: 3 Sayfa Aralığı: 107 - 113 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022
The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer
Öz: p53 gen mutasyonları malignitelerde en sık görülen genetik bozukluktur. Bu çalışmada serum anti-p53 antikor (Ab) düzeyinin tanısal değerinin araştırılması, serum anti-p53 Ab düzeyi ile SUVmax, SUVave, metabolik tümör volümü, total lezyon glikolizi (TLG) ve tümör boyutu gibi kantitatif pozitron emisyon tomografisi (PET) parametreleri arasındaki ilişkinin değerlendirilmesi amaçlanmıştır. Yöntem: Serum anti-p53 Ab düzeyi üç grupta çalışıldı. Birinci grupta akciğer kanseri nedeniyle evreleme için 18F-florodeoksiglukoz (FDG) PET/bilgisayarlı tomografi (BT) görüntülemesi yapılan hastalar, ikinci grupta ise toraks BT'de şüpheli pulmoner nodül saptanması nedeniyle tanı amacıyla 18F-FDG PET/BT yapılan ancak patolojik FDG tutulumu izlenmeyen hastalar (NAPN=FDG tutmayan pulmoner nodül) vardı. Üçüncü grubu sağlıklı gönüllüler oluşturdu.Bulgular: Bu çalışmaya akciğer kanseri olan 28 hasta (ortalama yaş: 62,5, aralık: 39-77 yıl), NAPN olan 28 hasta (ortalama yaş: 65, aralık: 33-79 yıl), ve 24 sağlıklı gönüllü (ortalama yaş: 62, aralık: 44-74 yıl) dahil edildi. Serum anti-p53 Ab düzeyi sağlıklı gönüllülerde düşük iken, akciğer kanserli hastalarda ve NAPN hastalarında yüksekti (p<0,05). Serum anti-p53 Ab düzeyi ve PET parametreleri değerlendirildiğinde; serum anti-p53 Ab düzeyi ile SUVmax, SUVave, TLG, tümör volümü ve akciğer kanserli hastalardaki tümör boyutu arasında anlamlı korelasyon saptanmadı (p>0,05). Ayrıca serum anti-p53 Ab düzeyi ile NAPN hastalarındaki lezyon boyutu arasında anlamlı farklılık yoktu (p>0,05). Sonuç: Serum anti-p53 Ab düzeyi ile PET parametreleri arasında anlamlı korelasyon olmadığı ve serum anti-p53 Ab düzeyinin akciğerde benign veya malign herhangi bir parankim patolojisinde yükseldiği bulundu. Bu sonuçlar serum anti-p53 Ab'nin malign akciğer lezyonları için bir belirteç olamayacağını düşündürmektedir
Anahtar Kelime: Konular:
Akciğer Kanserli Hastalarda Pozitron Emisyon Tomografisi Parametreleri ile Serum Anti-p53 Antikoru Arasındaki İlişkinin Diagnostik Değeri
Öz: Mutations in the p53 gene are the most commonly observed genetic abnormalities in malignancies. The purpose of this study was to assess the diagnostic value of serum anti-p53 antibody (Ab) along with the correlation between serum anti-p53 Ab level and quantitative positron emission tomography (PET) parameters such as maximum standardized uptake value (SUVmax), SUVave, metabolic tumor volume, total lesion glycolysis (TLG) and tumor size. Methods: Serum anti-p53 Ab level was studied in three groups. Patients who underwent 18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) imaging for staging of previously diagnosed lung cancer constituted the first group, while patients who underwent 18F-FDG PET/CT imaging for evaluation of suspicious pulmonary nodules detected on thorax CT and did not show pathologic FDG accumulation (NAPN=pulmonary nodule with non avid-FDG) were enrolled in the second group. The third group consisted of healthy volunteers.Results: Twenty-eight patients with lung cancer (median age: 62.5, range: 39-77years), 28 patients with NAPN (median age: 65, range: 33-79 years), and 24 healthy volunteers (median age: 62, range: 44-74 years) were enrolled in the study. The serum anti-p53 Ab level was low in healthy volunteers while it was higher in both lung cancer patients and NAPN patients (p<0.05). When serum anti-p53 Ab level and PET parameters were evaluated, there was no significant correlation between serum anti-p53 Ab level and SUVmax, SUVave, TLG, tumor volume and tumor size of patients with lung cancer (p>0.05). Besides, there was no significant difference between serum anti-p53 Ab level and lesion size of NAPN patients (p>0.05). Conclusion: It was determined that serum anti-p53 Ab levels are not significantly correlated with PET parameters, and that serum anti-p53 Ab levels increase in any benign or malignant lung parenchyma pathology as compared to healthy volunteers. These results indicate that this Ab cannot be used as a predictor of malignancy in a lung lesion
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- Rolfo C, Passiglia F, Ostrowski M, Farracho L, Ondoichova T, Dolcan A, Castiglia M, Remmen R, Papadimitriou K, Pauwels P. Improvement in lung cancer outcomes with targeted therapies: an update for family physicians. J Am Board Fam Med 2015;28:124-133.
- Zhu SH, Zhang Y, Yu YH, Fu Z, Kong L, Han DL, Fu L, Yu JM, Li J. FDG PET-CT in non-small cell lung cancer: relationship between primary tumor FDG uptake and extensional or metastatic potential. Asian Pac J Cancer Prev 2013;14:2925-2929.
- Liao S, Penney BC, Zhang H, Suzuki K, Pu Y. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer. Acad Radiol 2012;19:69-77.
- Zaizen Y, Azuma K, Kurata S, Sadashima E, Hattori S, Sasada T, Imamura Y, Kaida H, Kawahara A, Kinoshita T, Ishibashi M, Hoshino T. Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy. Eur J Radiol 2012;81:4179-4184.
- Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, Allen J, Thorpe AJ, Hamilton-Fairley G, Parsy-Kowalska CB, MacDonald IK, Jewell W, Maddison P, Robertson JF. EarlyCDT(R)-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol 2012;33:1319-1326.
- Ciancio N, Galasso MG, Campisi R, Bivona L, Migliore M, Di Maria GU. Prognostic value of p53 and Ki67 expression in fiberoptic bronchial biopsies of patients with non small cell lung cancer. Multidiscip Respir Med 2012;7:29.
- Neri M, Betta P, Marroni P, Filiberti R, Cafferata M, Mereu C, Ivaldi G, Montanaro F, Puntoni R, Paganuzzi M. Serum anti-p53 autoantibodies in pleural malignant mesothelioma, lung cancer and non-neoplastic lung diseases. Lung Cancer 2003;39:165-172.
- Wu M, Mao C, Chen Q, Cu XW, Zhang WS. Serum p53 protein and anti-p53 antibodies are associated with increased cancer risk: a case- control study of 569 patients and 879 healthy controls. Mol Biol Rep 2010;37:339-343.
- Lei QQ, Liu JW, Zheng H. Potential role of anti-p53 antibody in diagnosis of lung cancer: evidence from a bivariate meta-analysis. Eur Rev Med Pharmacol Sci 2013;17:3012-3018.
- Yao Y, Fan Y, Wu J, Wan H, Wang J, Lam S, Lam WL, Girard L, Gazdar AF, Wu Z, Zhou Q. Potential application of non-small cell lung cancer-associated autoantibodies to early cancer diagnosis. Biochem Biophys Res Commun 2012;423:613-619.
- Chapman CJ, Thorpe AJ, Murray A, Parsy-Kowalska CB, Allen J, Stafford KM, Chauhan AS, Kite TA, Maddison P, Robertson JF. Immunobiomarkers in small cell lung cancer: potential early cancer signals. Clin Cancer Res 2011;17:1474-1480.
- Maddau C, Confortini M, Bisanzi S, Janni A, Montinaro F, Paci E, Pontenani G, Rulli P, Salani A, Zappa M, Benvenuti A, Carozzi FM. Prognostic significance of p53 and Ki-67 antigen expression in surgically treated non-small cell lung cancer: immunocytochemical detection with imprint cytology. Am J Clin Pathol 2006;125:425-431.
- Agaylan A, Binder D, Sauer M, Neuweiler H, Meyer O, Kiesewetter H, Salama A. A highly sensitive particle agglutination assay for the detection of P53 autoantibodies in patients with lung cancer. Cancer 2007;110:2502-2506.
- Gomez AM, Jarabo Sarceda JR, Garcia-Asenjo JA, Fernandez C, Hernandez S, Sanz J, Fernandez E, Calatayud J, Torres A, Hernando F. Relationship of immunohistochemical biomarker expression and lymph node involvement in patients undergoing surgical treatment of NSCLC with long-term follow-up. Tumour Biol 2014;35:4551- 4559.
- Gao WM, Mady HH, Yu GY, Siegfried JM, Luketich JD, Melhem MF, Keohavong P. Comparison of p53 mutations between adenocarcinoma and squamous cell carcinoma of the lung: unique spectra involving G to A transitions and G to T transversions in both histologic types. Lung Cancer 2003;40:141-150.
- Breuer RH, Snijders PJ, Sutedja TG, Linden H, Risse EK, Meijer CJ, Postmus PE, Smit EF. Suprabasal p53 immunostaining in premalignant endobronchial lesions in combination with histology is associated with bronchial cancer. Lung Cancer 2003;40:165-172.
- Mattioni M, Chinzari P, Soddu S, Strigari L, Cilenti V, Mastropasqua E. Serum p53 antibody detection in patients with impaired lung function. BMC Cancer 2013;13:62.
- Kumar S, Mohan A, Guleria R. Prognostic implications of circulating anti-p53 antibodies in lung cancer--a review. Eur J Cancer Care (Engl) 2009;18:248-254.
- Park Y, Kim Y, Lee JH, Lee EY, Kim HS. Usefulness of serum anti-p53 antibody assay for lung cancer diagnosis. Arch Pathol Lab Med 2011;135:1570-1575.
- Gibbons DL, Byers LA, Kurie JM. Smoking, p53 mutation, and lung cancer. Mol Cancer Res 2014;12:3-13.
- Koumenis C, Alarcon R, Hammond E, Sutphin P, Hoffman W, Murphy M, Derr J, Taya Y, Lowe SW, Kastan M, Giaccia A. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 2001;21:1297-1310.
- Tsutani Y, Miyata Y, Misumi K, Ikeda T, Mimura T, Hihara J, Okada M. Difference in prognostic significance of maximum standardized uptake value on [18F]-fluoro-2-deoxyglucose positron emission tomography between adenocarcinoma and squamous cell carcinoma of the lung. Jpn J Clin Oncol 2011;41:890-896.
- Graham MM. Quantitation of PET Data in Clinical Practise. In: Shreve P, Townsend DW (eds). Clinical PET-CT in Radiology. New York, Springer Science+Busines Media LLC, 2011:163-180.
- Van de Wiele C, Kruse V, Smeets P, Sathekge M, Maes A. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging 2013;40:290-301.
- Taylor MD, Smith PW, Brix WK, Wick MR, Theodosakis N, Swenson BR, Kozower BD, Lau CL, Jones DR. Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer. J Thorac Cardiovasc Surg 2009;137:43-48.
- Duan XY, Wang W, Wang JS, Shang J, Gao JG, Guo YM. Fluorodeoxyglucose positron emission tomography and chemotherapy-related tumor marker expression in non-small cell lung cancer. BMC Cancer 2013;13:546.
- Zhou X, Xie W, Li Q, Zhang Y, Zhang J, Zhao X, Liu J, Huang G. TIGAR is correlated with maximal standardized uptake value on FDG-PET and survival in non-small cell lung cancer. PLoS One 2013;8:e80576.
- Watanabe K, Nomori H, Ohtsuka T, Naruke T, Ebihara A, Orikasa H, Yamazaki K, Uno K, Kobayashi T, Goya T. [F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas. Jpn J Clin Oncol 2006;36:403-409.
- Li XF, Du Y, Ma Y, Postel GC, Civelek AC. (18)F-fluorodeoxyglucose uptake and tumor hypoxia: revisit (18)f-fluorodeoxyglucose in oncology application. Transl Oncol 2014;7:240-247.
| APA | HASBEK Z, DOGAN O, Sari I, YÜCEL B, ŞEKER M, Turgut B, BERK S, Silig Y (2016). The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer. , 107 - 113. |
| Chicago | HASBEK Zekiye,DOGAN OMER TAMER,Sari Ismail,YÜCEL BİRSEN,ŞEKER Mehmet Metin,Turgut Bülent,BERK Serdar,Silig Yavuz The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer. (2016): 107 - 113. |
| MLA | HASBEK Zekiye,DOGAN OMER TAMER,Sari Ismail,YÜCEL BİRSEN,ŞEKER Mehmet Metin,Turgut Bülent,BERK Serdar,Silig Yavuz The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer. , 2016, ss.107 - 113. |
| AMA | HASBEK Z,DOGAN O,Sari I,YÜCEL B,ŞEKER M,Turgut B,BERK S,Silig Y The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer. . 2016; 107 - 113. |
| Vancouver | HASBEK Z,DOGAN O,Sari I,YÜCEL B,ŞEKER M,Turgut B,BERK S,Silig Y The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer. . 2016; 107 - 113. |
| IEEE | HASBEK Z,DOGAN O,Sari I,YÜCEL B,ŞEKER M,Turgut B,BERK S,Silig Y "The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer." , ss.107 - 113, 2016. |
| ISNAD | HASBEK, Zekiye vd. "The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer". (2016), 107-113. |
| APA | HASBEK Z, DOGAN O, Sari I, YÜCEL B, ŞEKER M, Turgut B, BERK S, Silig Y (2016). The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer. Molecular Imaging and Radionuclide Therapy, 25(3), 107 - 113. |
| Chicago | HASBEK Zekiye,DOGAN OMER TAMER,Sari Ismail,YÜCEL BİRSEN,ŞEKER Mehmet Metin,Turgut Bülent,BERK Serdar,Silig Yavuz The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer. Molecular Imaging and Radionuclide Therapy 25, no.3 (2016): 107 - 113. |
| MLA | HASBEK Zekiye,DOGAN OMER TAMER,Sari Ismail,YÜCEL BİRSEN,ŞEKER Mehmet Metin,Turgut Bülent,BERK Serdar,Silig Yavuz The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer. Molecular Imaging and Radionuclide Therapy, vol.25, no.3, 2016, ss.107 - 113. |
| AMA | HASBEK Z,DOGAN O,Sari I,YÜCEL B,ŞEKER M,Turgut B,BERK S,Silig Y The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer. Molecular Imaging and Radionuclide Therapy. 2016; 25(3): 107 - 113. |
| Vancouver | HASBEK Z,DOGAN O,Sari I,YÜCEL B,ŞEKER M,Turgut B,BERK S,Silig Y The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer. Molecular Imaging and Radionuclide Therapy. 2016; 25(3): 107 - 113. |
| IEEE | HASBEK Z,DOGAN O,Sari I,YÜCEL B,ŞEKER M,Turgut B,BERK S,Silig Y "The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer." Molecular Imaging and Radionuclide Therapy, 25, ss.107 - 113, 2016. |
| ISNAD | HASBEK, Zekiye vd. "The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer". Molecular Imaging and Radionuclide Therapy 25/3 (2016), 107-113. |
